Floatz logo

HYDROMORPHON

Opioid-Related Disorders

Johns Hopkins UniversitySmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Opioid-Related Disorders cohort.

Asset / SponsorPhaseRating
LIDOCAINE
University Medical Centre Ljubljana
Phase 4BB
Oxycodone
Member Companies of the Opioid PMR Consortium
Phase 4BB
CLOMIPHENE CITRATE
Weill Medical College of Cornell University
Phase 2B
OXYMORPHONE CII
Member Companies of the Opioid PMR Consortium
Phase 4B
Buspirone
Johns Hopkins University
Phase 1CC
IZAFLORTAUCIPIR
University of Pennsylvania
Early Phase 1CC

Same molecule, other indications

HYDROMORPHON is also rated in:

substance-related disorderDormant
BBB
Indicative ·
74 / 100
View asset →
Low Back PainDormant
BBB
Indicative ·
72 / 100
View asset →
Analgesics, OpioidDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →